| ABBVIE INC. DL-,01 |
| USA |
| Gesundheit |
| US00287Y1091 / A1J84E |
| 4AB (Frankfurt) / ABBV (NYSE) |
| FRA:4AB, ETR:4AB, 4AB:GR, NYSE:ABBV |
| S&P500 |
| https://www.abbvie.com/ |
|
AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Sk..
>Volltext.. |
| 383636.46 Mio. EUR |
| 438414.45 Mio. EUR |
| 55001.38 Mio. EUR |
| 25560.03 Mio. EUR |
| 3147.61 Mio. EUR |
| 1.78 EUR |
| 63791.06 Mio. EUR |
| 8222.32 Mio. EUR |
| 18582.74 Mio. EUR |
| 0.22 |
| 2.54% |
| -18.98% |
| 4.37 EUR |
| 2.72% |
| 2.81% |
| 15.04.26 - 1.467559€ 16.01.26 - 1.490914€ >weitere anzeigen... |
| - |
| ABBVIE |
| 15.07.26 |
|
||||
|